Cachexia

Cachexia Pipeline Market Research Report 2022: Comprehensive Insights on 15+ Companies and 15+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Growth hormone, Clinical trial, Therapy, AIDS, FDA, Hypothalamus, Cancer, News, Conditional sentence, Route of administration, GH, Growth, Route, Skin, ROA, Discovery, Patient, Appetite, Administration, Diagnosis, Adult, PF, Medical device, Pharmaceutical industry, Cachexia

The "Cachexia - Pipeline Insight, 2022," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cachexia pipeline landscape.

Key Points: 
  • The "Cachexia - Pipeline Insight, 2022," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cachexia pipeline landscape.
  • This segment of the Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • This segment of the report provides insights about the different Cachexia drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Cachexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Cancer Cachexia (CC) Epidemiology Research Report, 2019-2021 & 2022-2032 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 2, 2022
Health, Oncology, Table, Disease, United Kingdom, Epidemiology, Cachexia, Uranium, Dentistry

This "Cancer Cachexia (CC) - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Cancer Cachexia (CC) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Points: 
  • This "Cancer Cachexia (CC) - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Cancer Cachexia (CC) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Cancer Cachexia (CC) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries.
  • The Cancer Cachexia (CC) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM.
  • The Cancer Cachexia (CC) epidemiology covered in the report provides historical as well as forecasted Cancer Cachexia (CC) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Cachexia Pipeline Drugs and Companies 2021 - Phase, Mechanism of Action, Route, Licensing/Collaboration, Pre-clinical and Clinical Trials - ResearchAndMarkets.com

Retrieved on: 
Friday, February 18, 2022
Health, Pharmaceutical, Practice Management, Clinical Trials, Managed Care, Phase, Mall of America, News, Clinical trial, Company, Partnership, IV, Pharmaceutical industry, Cachexia

The "Cachexia Pipeline Drugs and Companies, 2021 - Phase, Mechanism of Action, Route, Licensing/Collaboration, Pre-clinical and Clinical Trials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cachexia Pipeline Drugs and Companies, 2021 - Phase, Mechanism of Action, Route, Licensing/Collaboration, Pre-clinical and Clinical Trials" report has been added to ResearchAndMarkets.com's offering.
  • It provides complete analysis on pipeline drugs detailing Phases, route of administration, mechanism of action, licensing and collaborations, clinical trial details including pre-clinical phase and clinical trials.
  • The Cachexia pipeline study analyzes and monitors the development landscape with the current status of each of the pipeline drugs under development for Cachexia.
  • Gain clear understanding of the Cachexia drugs through our expert coverage and in-depth analysis of drugs, companies and market trends
    Gain real-time insights into the global Cachexia pipeline news, developments and insights

Global Cancer Cachexia Market Research Report 2021 - Combination of Medical Therapeutics and Nutritional Interventions to Provide Better Outcome - ResearchAndMarkets.com

Retrieved on: 
Friday, January 21, 2022
Pharmaceutical, Health, Oncology, CAGR, Patient, Medroxyprogesterone, Incidence, Exercise, Combination, Cachexia, Megestrol, Appetite, Corticosteroid, Safety, Growth, Nipple stimulation, Weight gain, Diet, Attention, Cancer, Awareness, Dietary supplement, Pet, Pharmaceutical industry

The "Cancer Cachexia - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cancer Cachexia - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • This segment currently accounts for a 24.7% share of the global Cancer Cachexia market.
  • The market growth is favored by increasing attention on palliative cancer care along with rising incidence of cancer.
  • Recent therapy developments in the treatment of cancer cachexia have been combination therapies, supplemented with exercise routines and modification in diets.

Actimed Therapeutics Continues to Strengthen Intellectual Property Portfolio with Newly Granted US and Canadian Patents

Retrieved on: 
Wednesday, October 13, 2021
Michael Faraday, Company, Intellectual property, Musculoskeletal injury, Patent, Colorectal cancer, Muscle, Therapy, Amyotrophic lateral sclerosis, Cachexia, Wasting, CRC, Physician, Survival, NSCLC, Mortality, Cancer, Actas, ALS, Disease, Prevalence, Quality of life, Muscle weakness, Patient, Research, Pharmaceutical industry

This new intellectual property protection for treating injury-induced muscle weakness in the US will strengthen the Actimed global intellectual property portfolio around its lead asset, with the potential to address a new indication in the world's largest pharmaceutical market.

Key Points: 
  • This new intellectual property protection for treating injury-induced muscle weakness in the US will strengthen the Actimed global intellectual property portfolio around its lead asset, with the potential to address a new indication in the world's largest pharmaceutical market.
  • The new Canadian patent for treating ALS with S-oxprenolol (CA 2 906 206) follows from granted US and European patents to Actimed relating to S-oxprenolol for the treatment of ALS.
  • Actimed has retained global rights to S-oxprenolol in ALS, where loss of body mass and muscle wasting can impact survival.
  • Actimed retains global rights to S-oxprenolol in ALS, where loss of body mass and muscle wasting may impact survival.

Actimed Therapeutics Continues to Strengthen Intellectual Property Portfolio with Newly Granted US and Canadian Patents

Retrieved on: 
Wednesday, October 13, 2021
Michael Faraday, Company, Intellectual property, Musculoskeletal injury, Patent, Colorectal cancer, Muscle, Therapy, Amyotrophic lateral sclerosis, Cachexia, Wasting, CRC, Physician, Survival, NSCLC, Mortality, Cancer, Actas, ALS, Disease, Prevalence, Quality of life, Muscle weakness, Patient, Research, Pharmaceutical industry

This new intellectual property protection for treating injury-induced muscle weakness in the US will strengthen the Actimed global intellectual property portfolio around its lead asset, with the potential to address a new indication in the world's largest pharmaceutical market.

Key Points: 
  • This new intellectual property protection for treating injury-induced muscle weakness in the US will strengthen the Actimed global intellectual property portfolio around its lead asset, with the potential to address a new indication in the world's largest pharmaceutical market.
  • The new Canadian patent for treating ALS with S-oxprenolol (CA 2 906 206) follows from granted US and European patents to Actimed relating to S-oxprenolol for the treatment of ALS.
  • Actimed has retained global rights to S-oxprenolol in ALS, where loss of body mass and muscle wasting can impact survival.
  • Actimed retains global rights to S-oxprenolol in ALS, where loss of body mass and muscle wasting may impact survival.

BioInnovation Institute Creation House program announces intake of four innovative early stage start-up companies

Retrieved on: 
Thursday, September 23, 2021
Polyphagia, EUR, Cachexia, Charisma House, Orbit, Therapy, AKT, PWS, Solution, University of Copenhagen Faculty of Health and Medical Sciences, Chronic obstructive pulmonary disease, Novo Nordisk Foundation, BII, Cancer, Patient, Death, Lists of diseases, Physician, Health, Diabetes, AI, Prader–Willi syndrome, DKK, Environment, University, Primate, MVP, Company, Program, Woman, Life, Growth, Fertility, Ovarian follicle, Risk, Science, Burn, Weight gain, Research, Drug development, Obesity, Neptune, Survival, Mark (given name), Inotify, Quality of life, Pharmacotherapy, Rheumatoid arthritis, Chronic kidney disease, Pharmaceutical industry, Risk management, Fine chemical, Medical imaging

COPENHAGEN, Denmark, Sept. 23, 2021 /PRNewswire/ --BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its Creation House program.

Key Points: 
  • COPENHAGEN, Denmark, Sept. 23, 2021 /PRNewswire/ --BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its Creation House program.
  • "BII's Creation House program is designed to support start-ups in their journey, and essentially increase the likelihood of success.
  • Creation House is for companies with a solid, initial business plan.
  • Its diverse team brings venture capital, pharma and business expertise together to help early stage companies accelerate to the next level.

BioInnovation Institute Creation House program announces intake of four innovative early stage start-up companies

Retrieved on: 
Thursday, September 23, 2021
Polyphagia, EUR, Cachexia, Charisma House, Orbit, Therapy, AKT, PWS, Solution, University of Copenhagen Faculty of Health and Medical Sciences, Chronic obstructive pulmonary disease, Novo Nordisk Foundation, BII, Cancer, Patient, Death, Lists of diseases, Physician, Health, Diabetes, AI, Prader–Willi syndrome, DKK, Environment, University, Primate, MVP, Company, Program, Woman, Life, Growth, Fertility, Ovarian follicle, Risk, Science, Burn, Weight gain, Research, Drug development, Obesity, Neptune, Survival, Mark (given name), Inotify, Quality of life, Pharmacotherapy, Rheumatoid arthritis, Chronic kidney disease, Health insurance, Pharmaceutical industry, Risk management, Fine chemical, Medical imaging

COPENHAGEN, Denmark, Sept. 23, 2021 /PRNewswire/ -- BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its Creation House program. Creation House consists of a founder-friendly convertible loan of DKK 10M and 18 months incubation at BII with access to labs and office space, business development support, and BII partners. The program allows participants to meet and interact with BII's network of investors, industry partners, alumni and fellow entrepreneurs across its other programs, and is specifically designed to guide companies to a competitive international level and prepare teams for discussions with investors ahead of series A financing rounds.

Key Points: 
  • COPENHAGEN, Denmark, Sept. 23, 2021 /PRNewswire/ --BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its Creation House program.
  • "BII's Creation House program is designed to support start-ups in their journey, and essentially increase the likelihood of success.
  • Creation House is for companies with a solid, initial business plan.
  • Its diverse team brings venture capital, pharma and business expertise together to help early stage companies accelerate to the next level.

BioDelivery Sciences to Exhibit Three Scientific Posters Comparing BELBUCA® to Oxycodone at the PAINWeek 2021 Conference

Retrieved on: 
Tuesday, September 7, 2021

We are pleased to share these data with healthcare professionals who treat chronic pain patients at this years PAINWeek Conference.

Key Points: 
  • We are pleased to share these data with healthcare professionals who treat chronic pain patients at this years PAINWeek Conference.
  • Assess patients risk prior to prescribing BELBUCA and monitor patients regularly for these behaviors and conditions.
  • To report SUSPECTED ADVERSE REACTIONS, contact BioDelivery Sciences International, Inc. at 1-800-469-0261 or FDA at 1-800-FDA-1088 or www.fda.gov/safety/medwatch .
  • BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions.

Endevica Bio Reports TCMCB07 Preserves Lean Body Mass in Preclinical Cancer Cachexia Study

Retrieved on: 
Tuesday, August 31, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Peptide, Quality of life, Cancer, Cachexia, Family, Maintenance, Oregon, Death, Safety, Head, Bio, Patient, CEO, Traffic barrier, Conference, Half-life, Oregon Health & Science University, Encephalitis, Ponce Health Sciences University, Oregon Health Plan, Dietary supplement, Pharmaceutical industry

The results were presented in a poster titled Melanocortin-4 receptor antagonist TCMCB07 preserves lean muscle mass during cancer cachexia .

Key Points: 
  • The results were presented in a poster titled Melanocortin-4 receptor antagonist TCMCB07 preserves lean muscle mass during cancer cachexia .
  • The researchers evaluated efficacy of TCMCB07 with subcutaneous administration in two recently developed mouse cachexia models of orthotopic pancreatic cancer and head and neck cancer.
  • The data demonstrate that TCMCB07 can preserve lean mass as well as attenuate muscle wasting and body weight loss during cancer cachexia.
  • The authors concluded that TCMCB07 is a promising drug candidate with universal effects on treating cancer cachexia.